Daily Coverage on Healthcare Stocks: Spectral Medical, ProMIS Neurosciences, GeneNews, and Novadaq Technologies

LONDON, UK / ACCESSWIRE / June 19, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select stocks with the Medical Diagnostics & Research industry and that trades on the Toronto Exchanges. This Morning, our team has regrouped these stocks for study: Spectral Medical, ProMIS Neurosciences, GeneNews, and Novadaq Technologies. Register for these free reports at:

http://protraderdaily.com/register/

On Friday, June 16, 2017, the Toronto Exchange Composite Index was up 0.21%, finishing the day at 15,192.54.

Additionally, the Healthcare index was slightly up by 0.53%, ending the session at 64.88.

Pro-Trader Daily’s complimentary research reports on the following stocks are now available: Spectral Medical Inc. (TSX: EDT), ProMIS Neurosciences Inc. (TSX: PMN), GeneNews Ltd (TSX: GEN), and Novadaq Technologies Inc. (TSX: NDQ). Sign up now for your free membership and research reports at:

http://protraderdaily.com/register/

Spectral Medical Inc.

Toronto, Canada headquartered Spectral Medical Inc.’s stock fell 6.25%, to finish Friday’s session at $0.45 with a total volume of 69,921 shares traded. Spectral Medical’s shares have gained 26.76% in the past three months. Shares of the Company, which focuses on the development and commercialization of theranostic treatment for septic shock in North America, are trading above its 200-day moving average. Spectral Medical’s 50-day moving average of $0.50 is above its 200-day moving average of $0.38. See our research report on EDT.TO at:

http://protraderdaily.com/optin/?symbol=EDT

ProMIS Neurosciences Inc.

On Friday, shares in Toronto, Canada headquartered ProMIS Neurosciences Inc. recorded a trading volume of 436,330 shares, which was higher than their three months average volume of 425,803 shares. The stock ended the day 5.00% lower at $0.29. ProMIS Neurosciences’ stock has surged 64.71% in the last three months and 154.55% in the previous one year. Shares of the Company, which discovers and develops precision medicine therapeutics for treatment of neurodegenerative diseases, primarily Alzheimer’s disease and amyotrophic lateral sclerosis, are trading above its 200-day moving average. The stock’s 50-day moving average of $0.31 is above its 200-day moving average of $0.21. The complimentary research report on PMN.TO at:

http://protraderdaily.com/optin/?symbol=PMN

GeneNews Ltd

On Friday, shares in Markham, Canada-based GeneNews Ltd ended the session 2.94% lower at $0.17 with a total volume of 361,550 shares traded. Shares of the Company, which focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications, are trading below its 50-day and 200-day moving averages. Furthermore, the stock’s 200-day moving average of $0.33 is greater than its 50-day moving average of $0.24. Register for free and access the latest research report on GEN.TO at:

http://protraderdaily.com/optin/?symbol=GEN

Novadaq Technologies Inc.

Mississauga, Canada headquartered Novadaq Technologies Inc.’s stock closed the day 1.37% lower at $7.90. The stock recorded a trading volume of 9,300 shares, which was above its three months average volume of 5,674 shares. Shares of the company, which develops, manufactures, and markets fluorescence imaging products for use by surgeons in the operating room and other clinical settings in the US and internationally, are trading below their 50-day and 200-day moving averages. Moreover, the stock’s 200-day moving average of $9.59 is greater than its 50-day moving average of $9.55. Get free access to your research report on NDQ.TO at:

http://protraderdaily.com/optin/?symbol=NDQ

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 466107